Maravai acquires MyChem for $240M cash; expands ultra-pure nucleotides for mRNA therapeutics

MARAVAI LIFESCIENCES HOLDINGS, INC.

Purchase price $240M cash at close plus contingent consideration based on future conditions.
MyChem provides ultra-pure nucleotides for diagnostics, pharma, genomics; complements Maravai's TriLink mRNA technologies.
MyChem to become part of TriLink's Nucleic Acid Production segment; founder-led team stays on.
Deal strengthens Maravai's end-to-end mRNA supply chain and adds GMP manufacturing capability.
Advisors: Jefferies & Kirkland & Ellis for Maravai; BroadOak & Morrison & Foerster for MyChem.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.